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were 7.64% for GLAR and 7.87% for DET at the follow-up
visit. After adjusting for baseline characteristics and HbA1c and
concomitant antidiabetic medications during the follow-up
period, A1C remained lower in GLAR versus DET (7.06 vs
7.84%, P = 0.0178). Total insulin dose in GLAR was increased
from 45.3 U to 75.8 U at the follow-up visit and 33.5 U to
48.6 U in DET. Adjusted weight was 101.2 kg for GLAR and
97.1 kg for DET. CONCLUSIONS: Initiation of GLAR relative
to DET in T2D patients is associated with greater improvement
in glycemic control achieved within six months. More exenatide
use in DET relative to GLAR may possibly explain the group
difference in body weight. This analysis was conducted in a single
clinical practice hence further studies are needed to determine
reproducibility of the ﬁndings.
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OBJECTIVES: A meta-analysis of Pioglitazone and Rosiglita-
zone in patients with type 2 diabetes was conducted to evaluate
the effects of each drug on glycemic control, lipids, blood pres-
sure, and weight. In addition, this study was aimed to identify if
there is an ethnic difference in the effects between Asian and
Caucasian patients by subgroup analysis. METHODS: Among
the randomized controlled trials of Pioglitazone or Rosiglitazone
which had been published before February 2008, 63 randomized
controlled trials that were eligible for the inclusion/exclusion
criteria were collected. For quantitative meta-analysis, the
weighted pooled effect sizes and their 95% conﬁdence intervals
were calculated. RESULTS: Glucose lowering effect was higher
in Rosiglitazone, whereas Pioglitazone produced a more favor-
able lipid proﬁle. Both thiazolidinediones demonstrated similar
increases in body weight. The effect on blood pressure was
slightly higher in Pioglitazone. Regarding the effects of Pioglita-
zone, the pooled effect sizes of Pioglitazone 15 mg were very
similar for two different ethnic groups in all parameters. When
the effects of Pioglitazone in Caucasian patients group at dose of
30 mg and Asian patients group at dose of 15 mg were com-
pared, most of the overall effects sizes were higher in Caucasian
patients group than that of Asian patients group. In case of
Rosiglitazone, the pooled effect sizes of Asian patients group
administered 4 mg were higher than Caucasian patients group
administered the same dose. Furthermore, in comparing the
effect sizes of Asian patients group administered 4 mg and Cau-
casian patients group administered 8 mg, the effect sizes were
rather similar than they administered the same dose. CONCLU-
SIONS: The effects of Pioglitazone on the cardiovascular risk
factors are almost the same in different ethnic groups, whereas
those of Rosiglitazone varies with ethnicity. In this regards, well-
designed head-to-head comparative trials as well as long-term
cardiovascular outcome studies should be conducted in order to
accurately determine the various effects of the two thiazolidinedi-
ones on different ethnic groups.
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OBJECTIVES: The objective was to estimate the long-term clini-
cal outcomes in pharmaceutical treatment naïve type 2 diabetes
patients when initiated with biphasic insulin aspart (BIAsp) in a
secondary care setting in urban China. METHODS: A validated
computer simulation model of diabetes (the CORE Diabetes
Model) was used to make long-term projections of clinical out-
comes based on patient characteristics (mean age 49.7 years, time
since diagnosis 1.61 years, HbA1c 9.86%, BMI 24.62 kg.m-2)
and treatment effects of BIAsp (HbA1c improvement of 3.27
percentage points, an increase in hypoglycaemic events of 2.4 per
patient-year). All background and treatment data were obtained
from the Chinese part of the IMPROVE study (n = 7012). Treat-
ment management practices were taken from Chinese urban
hospitals. RESULTS: Superior glycemic control with BIAsp led to
a delay in the onset of diabetes-related complications by 0.31
years (1.16 vs 0.85), e.g. the delay of onset to neuropathy, myo-
cardial infarction and stroke were 1.09, 0.55, and 0.41 years,
respectively. The cumulative incidence of complications was pro-
jected to decrease with BIAsp in the majority of parameters
studied e.g. the incidence of neuropathy was decreased by 9.3%.
Life expectancy increased from 13.62 to 14.05 years. Quality-
adjusted life years (QALYs) (mean  sd) increased by 0.772
(9.01  0.171 vs 8.24  0.146). CONCLUSIONS: The long
term health outcome projections based on surrogate endpoints
reported in the Chinese cohort of the IMPROVE study, indicate
that initiating treatment with BIAsp in treatment naïve (including
OAD naïve) type 2 diabetes patients will improve life expectancy
and quality-adjusted life years, delay the onset of diabetes related
complications, and reduce their cumulative incidence over
patient lifetimes.
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OBJECTIVES: To assess diabetes disease burden and associated
treatment patterns among six European nations. METHODS: A
large multi-country online cross-sectional survey of approxi-
mately 175,000 adults was conducted in 2007 in France,
Germany, Italy, Spain, UK and the The Netherlands by TNS
Healthcare. The survey enabled TNS to build an epidemiological
database based on its proprietary European Healthcare Panel
(EHP) of consumers in these 6 countries. The data is representa-
tive of population gender and age (18–24, 25–34, 35–44, 45–54,
55–64, 65–69 yrs) strata in respective countries, ensured by sam-
pling and intensive panel management. The survey collected
information on select health conditions (incl. diabetes; in the past
12-months) and health care-utilization. RESULTS: Diabetes
disease prevalence varied widely between the 6 nations, as
follows (All pts, Males/Females, proportion type 1/type
2/Gestational/Unknown): Italy: 4%, 5%/3%, 28%/61%/3%/
8%; France: 5%, 5%/4%, 21%/63%/4%/12%; Spain: 5%,
6%/4%, 18%/66%/3%/13%; The Netherlands: 5%, 6%/5%,
13%/84%/1%/1%; Germany: 6%, 6%/5%, 14%/81%/1%/4%;
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UK: 7%, 4%/6%, 16%/79%/2%/4%. Within each country,
burden of type 2 diabetes tended to increase with age among
diabetic individuals (all-age, 18–24, 25–34, 35–44, 45–54,
55–64, 65–69 yrs: % pts): Italy: 61%, 17%, 16%, 31%, 66%,
79%, 61%; France: 63%, 7%, 19%, 46%, 61%, 73%,
76%; Spain: 66%, 18%, 16%, 44%, 75%, 68%, 93%; UK:
79%, 10%, 34%, 64%, 84%, 89%, 93%; Germany: 81%, 22%,
27%, 60%, 82%, 91%, 85%; The Netherlands: 84%, 50%,
50%, 71%, 86%, 89%, 92%. Type of treatment observed
among type 1/type 2 diabetics varied across the countries (not
mutually exclusive: % using Dietary restrictions/exercise, Oral-
therapy/oral-antidiabetics, Insulin therapy): The Netherlands:
type 1—16%, 4%, 92%, type 2—39%, 63%, 22%; UK: type
1—19%, 13%, 81%, type 2—39%, 62%, 16%; Spain:
type 1—33%, 13%, 73%, type 2—57%, 61%, 17%; Germany:
type 1—19%, 17%, 79%, type 2—61%, 54%, 25%;
France: type 1—52%, 44%, 35%, type 2—66%, 78%, 16%;
Italy: type 1—58%, 27%, 44%, type 2—79%, 77%,
14%. Among those using medications to manage diabetes, pre-
scription medicines predominated (range: 74% (Spain) to 86%
(The Netherlands)); use of OTC-products/complementary-
therapy was rare (<1%–3%), and so as herbal-therapy (<1%–
4%, except in Spain (12%)). CONCLUSIONS: Diabetes disease
burden appear to be substantial in European nations studied,
with type 2 diabetes burden increasing with age. The reported
treatment patterns varied dramatically. With the aging European
population, appropriate interventions, outcome evaluations and
cost-effective diabetes management strategies are warranted to
alleviate this burden.
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OBJECTIVES: This study aimed to model the increase in
osteoporosis-related fractures and the associated costs related
with aging and testosterone deﬁciency (TD) in the male popu-
lation above 65 years in the Brazilian Private Health System
(PHS). METHODS: Population-based prospective cohorts
established age-speciﬁc annual incidence rates of testosterone
deﬁciency and the prevalence of osteoporosis in men. Based on
these estimates, projections for the number of cases of men
with testosterone deﬁciency, osteoporosis and fractures in the
Brazilian male population above 65 years were computed. The
national costs associated with hip fractures have been previ-
ously recorded as R$ 24,051 (US$14,402) per event. RESULTS:
Among 1,164,379 male individuals above 65 years under the
Brazilian PHS, 27,130 new cases of TD would be expected in
one year. Considering an osteoporosis incidence of 6% and
12.3% for men with normal and deﬁcient testosterone, respec-
tively, 1709 new cases of osteoporosis attributed to TD would
be expected. This would result in an annual absolute increase
of 0.16% in non-vertebral fracture incidence in men between
65–69 years; 0.24% between 70–74 years; 0.32% between
75–79 years and 0.40% above 80 years. Each of these absolute
increases represents a 105% relative increase in the incidence of
non-vertebral fractures between men with TD relative to men
without TD. Seventy-one new non-vertebral fractures and 13
new cases of hip fractures would be expected, resulting in
incremental costs of R$318,002 (US$190,420) for the Brazilian
PHS. CONCLUSIONS: Male aging is associated with gradual
decrease in circulating testosterone, which may be detrimental
to bone. This model suggests that, for the Brazilian male popu-
lation above 65 years, testosterone deﬁciency is associated with
a signiﬁcant increase in new cases of osteoporosis-related frac-
tures in one year. Diagnosis and proper treatment of this con-
dition could have a favorable impact in the prevention of this
costly complication.
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OBJECTIVES: Diabetes patients’ management is complex and
requires that many issues, beyond glycemic control, be
addressed. Management of lipid proﬁle is a crucial component of
cardiovascular (CV) risk reduction in diabetic population. We
assessed the characteristics of dyslipidemia among an adult type
2 diabetes mellitus (T2DM) population that added either sulpho-
nylurea (SU) or a PPARg agonist to previous metformin (MF)
therapy in Spain. METHODS: A retrospective clinical chart
review and patient survey during physician visits (June 2006-
February 2007) was conducted in Spain. Patients were aged 30
years at time of T2DM diagnosis and added SU or a PPARg
agonist to previous MF between 2001 and 2006. Patients with
gestational diabetes or T1DM were excluded. For the present
analysis patients with missing values for LDL-c, HDL-c or trig-
lycerides (TGs) were excluded. Individual patient lipid proﬁles
were compared with the recommended lipid targets for diabetic
patients by the latest ADA consensus. RESULTS: A total of 493
patients were recruited, and 338 included in this analysis.
Average age was 63.1 (SD 10.6) years, 46.7% were female, and
mean time from diabetes diagnosis was 8.6 (SD 5.3). The lipid
parameter most frequently not at target was LDL-c (79.6%),
followed by TGs (42.9%) and HDL-c (37.6%). 17.5% of
patients had the three lipid parameters out of goal, and 31.4%
had two of them not at target. Out of the 338 patients only 20 (a
6% approx.) presented all three lipid parameters at the recom-
mended level. CONCLUSIONS: diabetic patients that start oral
combination therapy with either MF+SU or MF + a PPARg
agonist, very frequently have their lipid parameters not at rec-
ommended level. A greater focus is required to comprehensively
manage their lipid proﬁle, and reduce the cardiovascular risk
associated with it.
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OBJECTIVES: Diabetic patients are at CHD greater risk than
the general population. Therefore these patients will beneﬁt
from optimal care based on CHD risk evaluation. We assessed
the potential impact of risk factors (RF) management on the
cardiovascular (CV) risk among T2DM population.
METHODS: A retrospective cohort study was conducted in
Spain (2006–2007). Patients were aged 30 years at time of
T2DM diagnosis and had added sulphonylurea or PPARg
agonist to previous metformin. Patient RFs were assessed for
attainment of guideline-deﬁned optimal values. The data for
these patients correspond to their last available measurements
before add-on therapy. Five-year CV risk was estimated with a
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